CIK 0001740279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 825462585
- Phone
- (646) 600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-30 | Roemer Alan S. Director | Option exercise · Series A Warrants (right to buy) | −102,459 | 0 | ||
| 2025-04-30 | Roemer Alan S. Director | Option exercise · Series B Warrants (right to buy) | −11,000 | 0 | ||
| 2025-04-30 | Brandt Peter C. Director | Option exercise | +81,967 | $0.18 | $15K | 599,571 |
| 2025-04-30 | Brandt Peter C. Director | Option exercise | +81,967 | $0.18 | $15K | 681,538 |
| 2025-04-30 | Brandt Peter C. Director | Option exercise · Series A Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-30 | Brandt Peter C. Director | Option exercise · Series B Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-27 | Lamb Lawrence EVP and CSO | Returned to the company · Series B Warrants (right to buy) | −1,639 | 0 | ||
| 2025-04-27 | Lamb Lawrence EVP and CSO | Grant or award · Series B Warrants (right to buy) | +1,639 | 1,639 | ||
| 2025-04-27 | Graff Jeremy R. Director | Returned to the company · Series B Warrants (right to buy) | −2,049 | 0 | ||
| 2025-04-27 | Graff Jeremy R. Director | Grant or award · Series B Warrants (right to buy) | +2,049 | 2,049 | ||
| 2025-04-27 | Epperly Corinne Director | Returned to the company · Series B Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-27 | Epperly Corinne Director | Grant or award · Series B Warrants (right to buy) | +81,967 | 81,967 | ||
| 2025-04-27 | Ho William Tai-Wei PRESIDENT AND CEO | Returned to the company · Series B Warrants (right to buy) | −81,967 | 0 | ||
| 2025-04-27 | Ho William Tai-Wei PRESIDENT AND CEO | Grant or award · Series B Warrants (right to buy) | +81,967 | 81,967 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Returned to the company · Series A Warrants (right to buy) | −12,295 | 0 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Grant or award · Series A Warrants (right to buy) | +12,295 | 12,295 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Returned to the company · Series B Warrants (right to buy) | −12,295 | 0 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Grant or award · Series B Warrants (right to buy) | +12,295 | 12,295 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Returned to the company · Series A Warrants (right to buy) | −15,000 | 5,492 | ||
| 2025-04-27 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Series A Warrants (right to buy) | +15,000 | 15,000 |
Page 3 of 9 · 179 trades